MIT Tech Review explores cellular reprogramming to reverse aging

A recent MIT Technology Review roundtable, featuring science editor Mary Beth Griggs and senior biotechnology reporter Jessica Hamzelou, delved into longevity's next frontier: cellular reprogramming. The discussion highlighted the escalating race to reverse aging, fueled by billions in venture capital and high-profile bets like Sam Altman's $180 million investment in a company focused on delaying death. Scientists are now exploring two main paths: partial reprogramming using Yamanaka factors and a newer, more accessible approach called chemical reprogramming, which uses small molecules to revert cells to a younger state without genetic manipulation. The field's ambition extends beyond lab experiments—David Sinclair, a prominent aging researcher, plans to test whole-body rejuvenation drugs in the upcoming XPrize competition. However, significant hurdles remain, including safety, scalability, and the timeline for human applications. The roundtable underscored that while experimental treatments are progressing, they are still years away from clinical reality. Related stories from MIT Technology Review also covered brain-computer chips in China, artificial wombs via 3D-printed chicken eggs, and the hidden sense of interoception, painting a broader picture of how biotechnology is pushing boundaries across health and longevity. The session, recorded on June 30, 2026, provided a balanced view: optimism about the science tempered with caution about the journey ahead.